Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema

PURPOSE: To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. METHODS: This retrospective study at the Medical University of Vienna included patients with DME who were switched from aflibercept 2 mg to faricimab. IRF dynamics and central subfield thickness (CST) were assessed after two faricimab injections. Eyes were categorized as prior responders or non-responders based on their anatomical response to the last aflibercept injection (≥20% CST reduction or CST ≤250 μm). Optical coherence tomography (OCT)-derived CST and quantitative IRF volumes were analysed at baseline and after two faricimab injections. Associations between CST and IRF changes were evaluated. RESULTS: Fifty-eight eyes of 45 patients (mean age 65.3 ± 10 years) were included, with 56 eyes previously treated with aflibercept. After two faricimab injections (mean follow-up 10.1 ± 2.2 weeks), CST and total IRF volume decreased significantly (p < 0.0001). CST reduction was strongly associated with IRF reduction in the central millimetre (estimate 1.00 [0.73-1.28], p < 0.0001), but less so with total IRF volume (estimate 0.22 [0.17-0.28], p < 0.0001). Responders (n = 28) showed greater CST reduction compared to non-responders (-105.6 ± 123.9 μm vs. -27.3 ± 60.1 μm; p = 0.0003) and lower total IRF volume after treatment (p = 0.029), with more consistent regional improvements. Non-responders showed smaller but still significant IRF reductions. CONCLUSIONS: Switching from aflibercept 2 mg to faricimab resulted in significant reductions in CST and IRF volumes after two injections with a more pronounced effect in previous responders. While CST closely reflected central changes, its weaker association with total IRF reduction indicates that quantitative fluid assessment may further refine evaluation of treatment response and retreatment decisions.

Authors

Institutions

Publication Details

Journal
Acta Ophthalmologica
Published
2026-11-14
DOI
https://doi.org/10.1111/aos.70270
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema

Andreas Pollreisz, Kim Lien Huber, Heiko Stino, Stefan Sacu et al.
Acta Ophthalmologica
Retinal Diseases and Treatments
article

Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema

Andreas Pollreisz, Kim Lien Huber, Heiko Stino, Stefan Sacu, Irene Steiner, Paul Widmann-Sedlnitzky, Katharina Kriechbaum, Antonia Tippow, Bianca Gerendas
article en

Abstract

PURPOSE: To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. METHODS: This retrospective study at the Medical University of Vienna included patients with DME who were switched from aflibercept 2 mg to faricimab. IRF dynamics and central subfield thickness (CST) were assessed after two faricimab injections. Eyes were categorized as prior responders or non-responders based on their anatomical response to the last aflibercept injection (≥20% CST reduction or CST ≤250 μm). Optical coherence tomography (OCT)-derived CST and quantitative IRF volumes were analysed at baseline and after two faricimab injections. Associations between CST and IRF changes were evaluated. RESULTS: Fifty-eight eyes of 45 patients (mean age 65.3 ± 10 years) were included, with 56 eyes previously treated with aflibercept. After two faricimab injections (mean follow-up 10.1 ± 2.2 weeks), CST and total IRF volume decreased significantly (p < 0.0001). CST reduction was strongly associated with IRF reduction in the central millimetre (estimate 1.00 [0.73-1.28], p < 0.0001), but less so with total IRF volume (estimate 0.22 [0.17-0.28], p < 0.0001). Responders (n = 28) showed greater CST reduction compared to non-responders (-105.6 ± 123.9 μm vs. -27.3 ± 60.1 μm; p = 0.0003) and lower total IRF volume after treatment (p = 0.029), with more consistent regional improvements. Non-responders showed smaller but still significant IRF reductions. CONCLUSIONS: Switching from aflibercept 2 mg to faricimab resulted in significant reductions in CST and IRF volumes after two injections with a more pronounced effect in previous responders. While CST closely reflected central changes, its weaker association with total IRF reduction indicates that quantitative fluid assessment may further refine evaluation of treatment response and retreatment decisions.

Acta Ophthalmologica
Medical University of Vienna (AT)
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon